Demant Valuation

Q: What is the Fair Price of DEMANC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

DEMANC (DKK259) is trading below our estimate of [[fair value]] (DKK474.5)

Is DEMANC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DEMANC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DEMANC (DKK259) is trading below our estimate of fair value (DKK474.5)

Significantly Below Fair Value: DEMANC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DEMANC?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for DEMANC. This is calculated by dividing DEMANC's market cap by their current preferred multiple.
What is DEMANC's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	DKK 55.99b

DEMANC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.1x
Enterprise Value/EBITDA	15.2x
PEG Ratio	1.8x

Price to Earnings Ratio vs Peers

How does DEMANC's PE Ratio compare to its peers?

The above table shows the PE ratio for DEMANC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	34.4x
SN. Smith & Nephew	43.3x	22.7%	UK£9.9b
NIOX NIOX Group	26.4x	15.8%	UK£290.0m
CTEC ConvaTec Group	39.4x	21.0%	UK£4.5b
EKF EKF Diagnostics Holdings	28.5x	n/a	UK£136.1m
DEMANC Demant	22.1x	12.5%	DKK 56.0b

Price-To-Earnings vs Peers: DEMANC is good value based on its Price-To-Earnings Ratio (22.1x) compared to the peer average (34.4x).

Price to Earnings Ratio vs Industry

How does DEMANC's PE Ratio compare vs other companies in the European Medical Equipment Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	22.9%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	22.9%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: DEMANC is good value based on its Price-To-Earnings Ratio (22.1x) compared to the European Medical Equipment industry average (29.3x).

Price to Earnings Ratio vs Fair Ratio

What is DEMANC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DEMANC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	22.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate DEMANC's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DEMANC forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	DKK 259.00	DKK 301.31 +16.3%	11.1%	DKK 370.00	DKK 250.00	n/a	16
Sep ’25	DKK 285.90	DKK 303.81 +6.3%	11.6%	DKK 370.00	DKK 230.00	n/a	16
Aug ’25	DKK 251.90	DKK 314.94 +25.0%	13.9%	DKK 381.00	DKK 230.00	n/a	16
Jul ’25	n/a	DKK 336.69 0%	14.1%	DKK 400.00	DKK 268.00	n/a	16
Jun ’25	DKK 328.10	DKK 337.31 +2.8%	14.3%	DKK 400.00	DKK 268.00	n/a	16
May ’25	n/a	DKK 334.75 0%	15.5%	DKK 400.00	DKK 240.00	n/a	16
Apr ’25	DKK 343.40	DKK 339.47 -1.1%	15.8%	DKK 405.00	DKK 240.00	n/a	17
Mar ’25	n/a	DKK 336.53 0%	15.1%	DKK 400.00	DKK 240.00	n/a	17
Feb ’25	n/a	DKK 298.71 0%	13.5%	DKK 355.00	DKK 235.00	n/a	17
Jan ’25	n/a	DKK 288.71 0%	15.1%	DKK 350.00	DKK 185.00	n/a	17
Dec ’24	n/a	DKK 286.76 0%	13.4%	DKK 335.00	DKK 185.00	n/a	17
Nov ’24	n/a	DKK 287.69 0%	15.4%	DKK 340.00	DKK 185.00	n/a	16
Oct ’24	n/a	DKK 286.47 0%	15.8%	DKK 340.00	DKK 185.00	n/a	15
Sep ’24	DKK 292.95	DKK 285.94 -2.4%	15.4%	DKK 340.00	DKK 185.00	DKK 285.90	16
Aug ’24	DKK 280.10	DKK 264.27 -5.7%	19.1%	DKK 330.00	DKK 180.00	DKK 251.90	15
Jul ’24	DKK 289.45	DKK 256.60 -11.3%	20.2%	DKK 330.00	DKK 180.00	n/a	15
Jun ’24	n/a	DKK 252.13 0%	20.9%	DKK 330.00	DKK 180.00	DKK 328.10	15
May ’24	DKK 289.20	DKK 230.79 -20.2%	19.4%	DKK 330.00	DKK 180.00	n/a	14
Apr ’24	n/a	DKK 222.00 0%	13.2%	DKK 275.00	DKK 180.00	DKK 343.40	13
Mar ’24	DKK 213.00	DKK 218.00 +2.3%	14.8%	DKK 275.00	DKK 180.00	n/a	14
Feb ’24	DKK 194.15	DKK 206.50 +6.4%	13.7%	DKK 254.00	DKK 170.00	n/a	14
Jan ’24	DKK 188.95	DKK 215.23 +13.9%	16.7%	DKK 285.00	DKK 165.00	n/a	13
Dec ’23	DKK 202.70	DKK 215.25 +6.2%	17.2%	DKK 285.00	DKK 165.00	n/a	12
Nov ’23	n/a	DKK 249.08 0%	19.9%	DKK 330.00	DKK 176.00	n/a	12
Oct ’23	DKK 182.00	DKK 270.36 +48.6%	13.2%	DKK 330.00	DKK 200.00	n/a	11
Sep ’23	n/a	DKK 278.09 0%	10.0%	DKK 330.00	DKK 232.00	DKK 292.95	11

Analyst Forecast: Target price is less than 20% higher than the current share price.